Brensocatib reduces the annualized rate of pulmonary exacerbations in patients with bronchiectasis compared to placebo, with rate ratios of 0.79 and 0.81 for 10 mg and 25 mg doses, respectively.

In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 ...

Neutrophils are the core airway inflammatory cell in bronchiectasis. The drug appeared safe, although with a somewhat higher incidence of hyperkeratosis. Targeting airway inflammation with ...

The ASPEN study, the largest clinical trial for bronchiectasis to date, has no approved therapies for this chronic lung condition characterized by frequent exacerbations that degrade lung function ...

Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo ...

Dr. Burton Dickey, a pulmonary and critical care physician at MD Anderson Cancer Center in Houston told the New York Times that when an infection occurs in a patient with bronchiectasis ...

multiple bronchiectasis, arterial hypertension and type II diabetes.” A cerebral stroke is when there is a loss of blood flow to the brain, and an irreversible cardiocirculatory collapse means ...

multiple bronchiectasis, arterial hypertension and type II diabetes.” Francis was seen publicly the day before, meeting briefly with Vice President JD Vance on Easter Sunday. “His entire life ...